T
SAGE

Tidemark’s Sage Therapeutics SAGE Stock Holding History

Tidemark’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-600
Closed -$5.47K – 697
2025
Q2 		$5.47K Hold
600
– – ﹤0.01% 509
2025
Q1 		$4.77K Buy
+600
New +$4.39K ﹤0.01% 529

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Tidemark's SAGE Position: Q3 2025 in Review

Tidemark sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 600 shares — an estimated $5.47K sold.

Tidemark first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $5.47K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Tidemark reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tidemark sold 600 Sage Therapeutics shares in Q3 2025, an estimated $5.47K.
  • Tidemark first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
  • Tidemark's Sage Therapeutics position peaked at $5.47K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Tidemark's 13F filing for Q3 2025, filed 3 Nov 2025.